A Phase 3 interventional study of P-3058 in Onychomycosis, sponsored by Polichem S.A.. Completed at 5 sites in 5 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-03-08.
Sponsored by Polichem S.A. (part of Almirall, S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Pediatric patients affected by mild-to-moderate distal subungual onychomycosis (DSO) or affected by white superficial onychomycosis (WSO), due to dermatophytes, will be treated topically with P-3058 nail solution according to the appropriate treatment schedule.
158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.
This study's enrollment of 20 is below the median of 60 across 143 interventional studies indexed under Onychomycosis.
Browse Onychomycosis studies →Polichem S.A. is the lead sponsor of 7 studies on the registry; none are open to participants now.
First submitted before Polichem S.A. became part of Almirall, S.A..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: P-3058
Local tolerability
Local tolerability at all treated nails by means of the Severity Score for Skin Irritation
Time frame: from week 4 up to maximum week 48 of treatment
Ran from Aug 2014 to primary completion in Sep 2017, 37 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.